Adicet Bio (ACET) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Company overview and technology

• Focuses on CAR gamma delta one T cells, showing strong proof of concept in oncology, especially NHL and MCL, with high CR rates and durable responses.

• Gamma delta one T cells offer tissue homing, potent cytotoxicity, and do not cause graft versus host disease.

• Two main branches: autoimmune diseases and solid tumors, both entering clinical stages.

• Manufacturing process enables consistent, scalable, off-the-shelf product with a 14-day production timeline.

• Off-the-shelf approach allows rapid product release and shipment to patients.

Clinical data and differentiation

• In NHL and MCL, PK profile of ADI-001 is consistent with autologous therapies, with higher Cmax at high doses than Yescarta.

• Gamma delta CAR T cells show seven-fold higher tissue concentration than Yescarta and achieve complete B cell depletion in blood and lymph nodes.

• Achieved 60% CR rate and 17.5 months median durability in MCL, with a favorable safety profile and minimal CRS/ICANS.

• CD20 targeting leads to complete B cell depletion, confirmed by lymph node biopsies at day 10 post-treatment.

• Tissue tropism enables effective B cell depletion in organs relevant to autoimmune diseases, such as kidneys and lungs.

Clinical development and pipeline

• Cleared six indications with FDA, including lupus nephritis, SLE, systemic sclerosis, myositis, and ANCA-associated vasculitis.

• Enrollment open for lupus nephritis; SLE, myositis, and systemic sclerosis to start in Q1 next year; ANCA-associated vasculitis in H2 next year.

• Initial autoimmune data expected in the first half of next year, primarily from lupus nephritis.

• Oncology program ADI-270 targets CD70 in clear cell RCC, using CD27 for enhanced sensitivity and a dominant negative TGF-beta receptor for tumor microenvironment resistance.

• Preliminary efficacy data for ADI-270 expected in the first half of next year.